Biotech | March 10, 2022
Gufic Biosciences collaborates with Selvax for cancer treatment
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Subscribe To Our Newsletter & Stay Updated
